Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Growth | Market Cap | Revenue | EBITDA | Earnings | EPS | Rev. Y/Y | Rev. 5Y | Earn. Y/Y | Earn. 5Y | Earnings Date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONC | BEONE MEDICINES LTD | $39.77B | $4.97B | $318.03M | $68.55M | $0.05 | 49.92% | 79.66% | N/A | N/A | 2026-04-01 | ||
| NVO | NOVO NORDISK A S | $219.81B | $48.90B | $24.13B | $16.21B | $3.65 | 19.98% | 18.48% | 14.67% | 19.71% | |||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $3.44B | $597.97M | $53.58M | $35.92M | $0.49 | 55.68% | N/A | N/A | N/A | 2026-03-03 | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $486.97M | $84.39M | $67.21M | $35.33M | $0.48 | 244.60% | 46.99% | N/A | N/A | 2026-03-11 | ||
| CORT | CORCEPT THERAPEUTICS INC | $4.19B | $741.17M | $65.98M | $104.65M | $1.00 | 17.92% | 15.79% | -26.47% | 1.03% | |||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $44.12B | $3.71B | $631.44M | $313.75M | $2.39 | 65.19% | 49.77% | N/A | N/A | |||
| VCEL | VERICEL CORP | $1.89B | $258.72M | $29.31M | $13.08M | $0.26 | 14.05% | 16.93% | 271.43% | 67.03% | 2026-02-26 | ||
| ARGX | ARGENX SE | $51.60B | $1.92M | $811.30M | $1.51B | $25.02 | -94.62% | -50.87% | N/A | N/A | 2026-02-26 | ||
| GMAB | GENMAB A | $18.73B | $3.72B | $1.54B | $963.00M | $1.55 | 19.19% | 21.32% | -12.23% | 8.69% | |||
| KRYS | KRYSTAL BIOTECH INC | $8.28B | $389.13M | $196.02M | $204.83M | $7.08 | 33.94% | N/A | 126.92% | N/A | 2026-03-02 | ||
| LGND | LIGAND PHARMACEUTICALS INC | $3.74B | $251.23M | $103.01M | $48.58M | $2.31 | 64.83% | 11.86% | -12.50% | 80.67% | 2026-03-04 | ||
| TECH | BIO-TECHNE CORP | $9.28B | $1.22B | $226.43M | $81.10M | $0.52 | 1.64% | 8.76% | -48.00% | -14.59% | |||
| ADMA | ADMA BIOLOGICS INC | $3.81B | $488.56M | $172.13M | $209.45M | $0.88 | 27.62% | 64.71% | 203.45% | N/A | 2026-03-19 | ||
| MNKD | MANNKIND CORP | $1.67B | $313.79M | $73.18M | $29.23M | $0.10 | 17.44% | 38.00% | 25.00% | N/A | 2026-03-03 | ||
| ABEO | ABEONA THERAPEUTICS INC | $277.46M | $400.00k | $89.85M | $82.35M | $1.59 | N/A | -43.59% | N/A | N/A | 2026-03-23 | ||
| HALO | HALOZYME THERAPEUTICS INC | $8.64B | $1.40B | $573.05M | $316.89M | $2.64 | 37.55% | 39.16% | -24.57% | 22.68% | 2026-02-24 | ||
| RPRX | ROYALTY PHARMA PLC | $26.15B | $2.38B | $1.08B | $770.95M | $1.79 | 5.06% | 2.30% | -6.77% | 6.28% | |||
| VCYT | VERACYTE INC | $2.89B | $495.14M | $57.00M | $30.32M | $0.39 | 16.41% | 34.46% | N/A | N/A | 2026-02-25 | ||
| XOMA | XOMA ROYALTY CORP | $301.53M | $47.11M | $26.75M | $16.60M | $0.81 | 118.02% | 84.11% | N/A | N/A | 2026-03-05 | ||
| NAGE | NIAGEN BIOSCIENCE INC | $399.03M | $124.71M | $22.69M | $20.43M | $0.27 | 36.04% | 16.99% | 2,600.00% | N/A | 2026-03-11 | ||
| PLX | PROTALIX BIOTHERAPEUTICS INC | $239.66M | $61.84M | $8.87M | $5.39M | $0.07 | 35.42% | 0.22% | N/A | N/A | 2026-03-12 | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.03B | $825.94M | $269.64M | $185.68M | $3.23 | 21.13% | 49.81% | 50.23% | N/A | 2026-03-03 | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $2.99B | $578.20M | $323.88M | $217.56M | $1.79 | 25.56% | 37.37% | 43.20% | 21.00% | 2026-03-18 | ||
| AUPH | AURINIA PHARMACEUTICALS INC | $1.89B | $265.81M | $103.52M | $77.84M | $0.58 | 20.62% | 369.11% | N/A | N/A | 2026-03-04 | ||
| APLS | APELLIS PHARMACEUTICALS INC | $2.81B | $1.02B | $93.37M | $44.99M | $0.35 | 42.11% | 335.88% | N/A | N/A | 2026-03-04 | ||
| CRMD | CORMEDIX INC | $564.92M | $214.30M | $112.26M | $162.50M | $2.27 | 1,647.67% | 300.38% | N/A | N/A | 2026-03-31 | ||
| REGN | REGENERON PHARMACEUTICALS INC | $83.75B | $14.34B | $5.82B | $4.50B | $43.07 | 0.99% | 11.04% | 5.31% | 5.70% | |||
| UTHR | UNITED THERAPEUTICS CORP | $20.50B | $3.13B | $1.77B | $1.27B | $28.48 | 13.50% | 17.29% | 17.15% | 21.79% | 2026-02-25 | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.88B | $3.09B | $772.70M | $520.42M | $2.72 | 12.39% | 10.68% | 60.00% | -10.40% | 2026-02-25 | ||
| ACAD | ACADIA PHARMACEUTICALS INC | $3.93B | $1.05B | $287.72M | $261.17M | $1.57 | 12.69% | 20.10% | 101.28% | N/A | 2026-03-02 | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $119.47B | $12.00B | $4.87B | $3.95B | $15.46 | 8.90% | 14.10% | N/A | 8.17% | |||
| INVA | INNOVIVA INC | $1.77B | $388.52M | $214.76M | $127.34M | $1.89 | 10.14% | 3.81% | 87.13% | -2.45% | 2026-03-04 | ||
| EXEL | EXELIXIS INC | $11.55B | $2.32B | $994.49M | $782.57M | $2.88 | 6.98% | 18.63% | 60.00% | 51.57% | |||
| MDXG | MIMEDX GROUP INC | $773.09M | $393.44M | $69.21M | $40.83M | $0.28 | 14.77% | 8.97% | -55.56% | N/A | 2026-03-04 | ||
| INCY | INCYTE CORP | $20.50B | $5.14B | $1.76B | $1.29B | $6.59 | 21.22% | 14.03% | 4,018.75% | N/A |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.